Aclaris Therapeutics Priced, Nasdaq: ACRS

Developing a proprietary hydrogen peroxide treatment for common skin lesions.

Industry: Health Care

Latest Trade: $26.98 0.00 (0.0%)

First Day Return: +0.5%

Return from IPO: +145.3%

Industry: Health Care

We are a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated topical drugs to address significant unmet needs in dermatology. Our lead drug candidate, A-101, is a proprietary high-concentration hydrogen peroxide topical solution that we are developing as a prescription treatment for seborrheic keratosis, a common non-malignant skin tumor. We have completed three Phase 2 clinical trials of A-101 in over 300 patients with SK. In these trials, following one or two applications of A-101, we observed clinically relevant and statistically significant improvements in clearing SK lesions on the face, trunk and extremities of the body. We plan to commence three Phase 3 clinical trials of A-101 in patients with SK in the first quarter of 2016 and, if the results of these trials are favorable, to submit a New Drug Application for A-101 for the treatment of SK to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2016. We also intend to develop A-101 as a prescription treatment for common warts and A-102, a proprietary gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. We recently in-licensed the exclusive, worldwide rights to inhibitors of the Janus kinase family of enzymes, for specified dermatological conditions. We plan to develop these JAK inhibitors, A-201 and A-301, as potential treatments for hair loss associated with an autoimmune skin disease known as alopecia areata and potentially for other dermatological conditions. We intend to in-license or acquire additional drug candidates for other dermatological conditions to build a fully integrated dermatology company.
more less
IPO News for Aclaris Therapeutics
more
IPO Data
IPO File Date 08/17/2015
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $55
IPO Data
IPO Date 10/06/2015
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $55
Underwriters
more
Company Data
Headquarters Malvern, PA
Founded 2012
Employees 11
Website www.aclaristx.com